Drug of Choice for Pseudomonas aeruginosa
For confirmed Pseudomonas aeruginosa infections in adults without drug allergies or renal impairment, use an antipseudomonal beta-lactam as monotherapy if the organism is susceptible and the patient is not in septic shock. The preferred agents are piperacillin-tazobactam, cefepime, ceftazidime, or a carbapenem (imipenem or meropenem) 1, 2, 3.
Treatment Algorithm Based on Clinical Severity
Non-Severe Infections (Not ICU, Hemodynamically Stable)
Monotherapy is appropriate once susceptibilities are known 4:
- Piperacillin-tazobactam 3.375g every 6h (or 4.5g every 6h for higher dosing) 1
- Cefepime 2g every 8-12h 1
- Ceftazidime 2g every 8h 1
- Meropenem 1g every 8h 1
- Imipenem 500mg every 6h or 1g every 8h 1
The choice among these should be guided by antimicrobial susceptibility testing results 4. Aminoglycoside monotherapy is strongly contraindicated 4.
Severe Infections (ICU, Septic Shock, High Mortality Risk)
Combination therapy with two antipseudomonal agents is recommended 3:
Preferred regimen:
- Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem)
- PLUS ciprofloxacin or levofloxacin 750mg daily 3
Alternative regimens:
- Antipseudomonal beta-lactam plus aminoglycoside (gentamicin 5-7mg/kg every 24h or tobramycin 5-7mg/kg every 24h) plus azithromycin 3
- Antipseudomonal beta-lactam plus aminoglycoside plus an antipneumococcal fluoroquinolone 3
Important caveat: Once the patient's septic shock resolves and susceptibilities confirm activity, de-escalate to monotherapy 4. The benefit of combination therapy is primarily to ensure appropriate initial coverage and reduce mortality in the most critically ill patients 2.
Multidrug-Resistant (MDR) Pseudomonas aeruginosa
For MDR strains with difficult-to-treat resistance patterns:
First-line newer agents (when susceptible):
- Ceftolozane-tazobactam - preferred for pneumonia 5, 6
- Ceftazidime-avibactam - equally effective for non-pulmonary infections 5, 6
- Imipenem-relebactam - may retain activity when others fail 6, 7
- Cefiderocol - particularly for metallo-beta-lactamase producers 5, 6, 7
For strains resistant to newer agents:
- If metallo-beta-lactamases present: cefiderocol is preferred 5, 6
- Alternative: aztreonam plus ceftazidime-avibactam combination 5
- Last resort: polymyxins (colistin or polymyxin B) with consideration of adjunctive inhaled therapy 4
Critical Considerations
Resistance development: P. aeruginosa can develop resistance during therapy in 30-50% of patients on monotherapy 2. However, combination therapy has not been proven to prevent this in clinical studies 2. The primary rationale for combination therapy is ensuring appropriate initial coverage in severe infections, not preventing resistance emergence.
Fluoroquinolone resistance: Significant declines in P. aeruginosa susceptibility to fluoroquinolones have occurred with widespread hospital use 2. Use ciprofloxacin or levofloxacin only if local susceptibility data confirm activity 2.
Aminoglycoside dosing: If used, employ once-daily dosing based on lean body mass (gentamicin/tobramycin 5-7mg/kg every 24h, amikacin 15-20mg/kg every 24h) with therapeutic drug monitoring 1.
Penicillin allergy: Substitute aztreonam for the beta-lactam in the regimens above 3.
Duration: Limit therapy to 7 days for most infections with good clinical response, though P. aeruginosa may require longer courses than other pathogens 1, 2.